Last updated: May 24, 2026
Nevirapine Drug Suppliers: Active Ingredient, Finished Dosage Forms, and Manufacturing Sources (API and Brands)
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in HIV-1 therapy. Supplier coverage is split between (1) nevirapine API producers and (2) finished-dose manufacturers for tablets and extended-release formulations sold under multiple global brands. Supplier availability varies by geography, registration status, and whether the product is marketed as immediate-release versus extended-release.
Who supplies nevirapine API (active pharmaceutical ingredient) and where are producers located?
Nevirapine API is supplied by specialized small-molecule manufacturers and generic API plants that support HIV product portfolios. The supplier list is typically found through procurement networks, drug master file (DMF) ownership, and regulatory submissions tied to source-of-material declarations.
What are the main nevirapine API supplier archetypes?
- Direct API manufacturers supplying nevirapine API under commercial contracts to formulators and branded-generic brands.
- API traders/distributors sourcing API from licensed plants and reselling into tenders and distributor channels.
- Integrated finished-dose manufacturers that also produce or qualify their own API for internal control (less common for nevirapine than for some newer oncology assets, but present in practice).
Which countries dominate nevirapine API supply?
Nevirapine API sourcing most commonly concentrates in regions with mature HIV generic manufacturing capacity, including:
- India
- China
- Israel
- South Korea
- EU-based CMOs that may not produce API but do supply API-to-finished blending, packaging, and quality release pathways
Which companies manufacture nevirapine tablets and extended-release formulations?
Nevirapine is marketed in immediate-release tablets and, in some markets, extended-release (XR) tablets. Finished-dose supply depends on the target market regulatory framework and product line strategy (HIV tender schedules and national formularies).
What finished dosage strengths and forms are typically sourced?
- Immediate-release tablets (strengths vary by country)
- Extended-release tablets (often used to improve dosing convenience)
- Oral formulations (some markets offer pediatric or alternative dosage forms)
How do market-specific listings affect who can supply?
Finished-dose suppliers must align with:
- local marketing authorization
- GMP compliance inspections
- pharmacovigilance obligations
- submission consistency (site of manufacture, batch release testing, stability programs)
Procurement tends to favor suppliers with:
- established tender track records
- robust quality documentation packages for importation
- supply continuity for public health contracts
What are the key nevirapine supplier qualification barriers (API and finished dose)?
Supplier onboarding in nevirapine is less about clinical IP and more about regulatory and quality readiness.
API qualification barriers
- DMF completeness (or CEP/ASMF alignment depending on jurisdiction)
- impurity profile control and batch-to-batch consistency
- solvent and polymorph control where applicable
- stability and re-test period support
- consistent particle size control for solid oral dosage performance
Finished-dose qualification barriers
- bioequivalence for generics where required
- dissolution specification alignment for IR vs XR
- container-closure and packaging validation
- subcontracting transparency (blend, compression, coating, packaging)
How does nevirapine supplier availability differ by geography and procurement channel?
Supplier sets differ depending on whether buyers are:
- national procurement agencies (public health tenders)
- wholesalers and distributors
- institutional hospitals
- NGO-managed HIV programs
- pharmacy supply chains
Common procurement pattern
- Buyers in high-volume tenders typically source from suppliers with proven import history and local regulatory clearance.
- Wholesalers often prefer suppliers with broad distribution footprints, faster lead times, and consistent back-stock.
What is the supplier risk profile for nevirapine (lead times, batch continuity, and shortages)?
Nevirapine supply risk is usually driven by:
- API plant scheduling and campaign-based production cycles
- quality deviations that delay batch release
- regulatory inspection outcomes
- demand volatility tied to national HIV program budgets
What signals matter for supplier continuity?
- history of batch release delays
- frequency of GMP remediation actions
- strength of stability coverage and ongoing validation
- availability of redundant API sources (secondary plants)
Which nevirapine brands and generic manufacturers are active globally?
Nevirapine is present in multiple branded and generic products worldwide. Active manufacturers often include:
- global generics firms with HIV portfolios
- regional companies focused on public health supply
- contract manufacturers for labeled products
A complete, firm-by-firm global supplier list requires market-by-market labeling and regulatory entry confirmation, because suppliers vary across:
- dosage form (IR vs XR)
- strength
- local label
- packaging format
How do you identify the actual nevirapine supplier behind a product in procurement?
Procurement due diligence typically triangulates:
- label and package insert
- site of manufacture named on regulatory documentation
- batch records availability through supplier audits
- DMF/ASMF linkage to the API plant for traceability
- GMP certificates and inspection history
What documents expose supplier identity fastest?
- Certificate of Analysis (CoA) and batch documentation
- GMP site certificate for the labeled manufacturer and key subcontractors
- registration dossier references for manufacturing sites
- DMF reference numbers or ASMF declarations (where used)
Key Takeaways
- Nevirapine supply splits into API production and finished-dose manufacturing, with sourcing shaped by regulatory registration and GMP qualification.
- Supplier availability depends on whether the buyer needs immediate-release or extended-release tablets, plus local market authorization requirements.
- The fastest way to identify the real supplier is through site-of-manufacture disclosures, DMF/ASMF linkage (for API), and audit-grade quality documentation (CoA, GMP certificates, batch release support).
- Supplier risk is dominated by batch continuity, quality deviation history, and inspection-driven delays, not by clinical IP.
FAQs
What is the difference between nevirapine immediate-release and extended-release suppliers?
IR and XR products often have different formulation know-how, dissolution specs, and sometimes different manufacturing sites and packaging controls, so supplier sets may not overlap.
Can one nevirapine finished-dose company use multiple API sources?
Yes in many supply chains, but regulatory approvals and validation requirements usually constrain changes; some suppliers maintain qualified secondary API plants.
How do buyers verify nevirapine API traceability?
Through batch documentation, CoA alignment to the declared API source, and DMF/ASMF linkage where applicable.
What tends to cause nevirapine supply shortages?
API plant downtime, quality/compliance events delaying batch release, and sudden tender demand changes in high-volume public health programs.
Which quality standards matter most for nevirapine procurement?
GMP compliance at the labeled manufacturing site, validated dissolution and release specs for the dosage form, and stability-supported shelf-life claims consistent with the packaging.
References
- World Health Organization. (n.d.). WHO Model List of Essential Medicines. https://www.who.int/
- FDA. (n.d.). Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
- EMA. (n.d.). Human medicines: regulatory information. https://www.ema.europa.eu/
